Morepen Labs files FY26 Annual Report; 41st AGM set for Sep 26, 2026

Pat NegativeExceptional ItemEbitda Margin CompressionResults View source PDF Explain this filing

MOREPENLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+7.7%Reaction day

₹103.95

prior close

₹111.29

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.6%+8.3% vs market

Pharmaceuticals peers, median of 171sector-0.2%+7.9% vs sector

On the reaction day the stock moved 8.3 pts more than Nifty Microcap 250 and 7.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.2

10m

+0.9

15m

-0.1

30m

+0.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+7.7-0.6+8.3-0.2+7.9

Next day

+12.8+0.0+12.8+0.2+12.6

+9.3+0.7+8.6+0.1+9.2

+14.5+1.1+13.4+0.6+13.9

+12.5+1.6+10.8+0.8+11.7

+12.6+1.5+11.1+0.0+12.5

+11.3+1.4+9.9+0.5+10.8

15d

+12.4+0.4+11.9+0.7+11.7

+30.6-1.4+32.0-2.1+32.7

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 171Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Morepen Labs filed FY25-26 Annual Report with 41st AGM notice (Sep 26 via video conferencing). Consolidated revenue nearly flat at about Rs 1,827 crore. Profit after tax fell about 20 percent to Rs 94.88 crore on API margin pressure. Standalone sales rose 8.39 percent; Medical Devices grew 20 percent. Key win: multi-year CDMO contract worth about Rs 825 crore from a global pharma firm. Final dividend Rs 0.20 per share.

Likely market impact

Mixed results: profit fell about 20 percent on margin pressure, but a big Rs 825 crore CDMO order signals strong future revenue visibility.